Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome.
Study Goal
The researchers aimed to compare the clinical benefits of three treatment modalities (diet alone, diet with myo-inositol, and diet with a combination of myo-inositol and D-chiroinositol) in overweight/obese women with PCOS.
Results Summary
All groups showed significant reductions in body weight, BMI, and waist/hip circumferences. The combination of MI+DCI with diet was most effective in restoring menstrual regularity and accelerating weight loss and fat mass reduction.
Population
Overweight/obese women with polycystic ovary syndrome (PCOS).
Effective Dosage
Group 2: MI 4 g + folic acid 400 µg daily; Group 3: MI 1.1 g + DCI 27.6 mg + folic acid 400 µg daily.
Duration
6 months.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
only diet | decrease | body weight | overweight/obese PCOS women | - | decreased significantly | #1 |
only diet | decrease | BMI | overweight/obese PCOS women | - | decreased significantly | #2 |
only diet | decrease | waist circumference | overweight/obese PCOS women | - | decreased significantly | #3 |
only diet | decrease | hip circumference | overweight/obese PCOS women | - | decreased significantly | #4 |
diet and myo-inositol (MI) 4 g + folic acid 400 µg daily | decrease | body weight | overweight/obese PCOS women | - | decreased significantly | #5 |
diet and myo-inositol (MI) 4 g + folic acid 400 µg daily | decrease | BMI | overweight/obese PCOS women | - | decreased significantly | #6 |
diet and myo-inositol (MI) 4 g + folic acid 400 µg daily | decrease | waist circumference | overweight/obese PCOS women | - | decreased significantly | #7 |
diet and myo-inositol (MI) 4 g + folic acid 400 µg daily | decrease | hip circumference | overweight/obese PCOS women | - | decreased significantly | #8 |
diet in association with MI 1.1 g + D-chiroinositol (DCI) 27.6 mg + folic acid 400 µg daily | decrease | body weight | overweight/obese PCOS women | - | decreased significantly | #9 |
diet in association with MI 1.1 g + D-chiroinositol (DCI) 27.6 mg + folic acid 400 µg daily | decrease | BMI | overweight/obese PCOS women | - | decreased significantly | #10 |
diet in association with MI 1.1 g + D-chiroinositol (DCI) 27.6 mg + folic acid 400 µg daily | decrease | waist circumference | overweight/obese PCOS women | - | decreased significantly | #11 |
diet in association with MI 1.1 g + D-chiroinositol (DCI) 27.6 mg + folic acid 400 µg daily | decrease | hip circumference | overweight/obese PCOS women | - | decreased significantly | #12 |
diet in association with MI 1.1 g + D-chiroinositol (DCI) 27.6 mg + folic acid 400 µg daily | increase | restoration of menstrual regularity | overweight/obese PCOS women | - | obtained in all patients | #13 |
MI+DCI in association with diet | increase | weight loss | overweight/obese PCOS women | - | seems to accelerate | #14 |
MI+DCI in association with diet | increase | fat mass reduction | overweight/obese PCOS women | - | seems to accelerate | #15 |
MI+DCI in association with diet | increase | percent lean mass | overweight/obese PCOS women | - | slight increase | #16 |
MI+DCI in association with diet | increase | restoring the regularity of the menstrual cycle | overweight/obese PCOS women | - | contributes significantly | #17 |
OBJECTIVE: To evaluate, in overweight/obese PCOS women, which of three distinct treatment modalities achieved the greatest clinical benefits in terms of clinical and body composition outcomes. PATIENTS AND METHODS: Forty-three polycystic ovary syndrome (PCOS) overweight/obese patients were randomly treated for 6 months with: only diet (Group 1, n = 21); diet and myo-inositol (MI) 4 g + folic acid 400 µg daily (group 2, n = 10); diet in association with MI 1.1 g + D-chiroinositol (DCI) 27.6 mg + folic acid 400 µg daily (group 3, n = 13). Menstrual cycle, Ferriman-Gallwey score, body mass index (BMI), waist circumference, hip circumference, waist-hip ratio (WHR), and body composition by bioimpedentiometry were measured at baseline, 3 and 6 months. RESULTS: Body weight, BMI, waist and hip circumferences decreased significantly in all groups. There was a significant difference between the 3 groups regarding the restoration of menstrual regularity (p = 0.02) that was obtained in all patients only in-group 3. CONCLUSIONS: MI+DCI in association with diet seems to accelerate the weight loss and the fat mass reduction with a slight increase of percent lean mass, and this treatment contributes significantly in restoring the regularity of the menstrual cycle.